We also analyzed the relationship between p53 and clinicopathological parameters; the results showed that p53 expression was significantly associated with more advanced TNM stages (I/II vs. III/IV, OR = 0.74, 95 % CI: 0.55–0.99), lymph node metastasis (OR = 0.77, 95 % CI: 0.66–0.90), and distant metastasis (OR = 0.46, 95 % CI: 0.26–0.80). Here, TP53 is linked to metastatic malignant neoplasm in the lymph nodes.